Scribe Therapeutics prices IPO at $15 per share on Nasdaq

Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage biotechnology company, priced its initial public offering of 8,580,000 shares of common stock at $15.00 per share, the high end of its projected range, according to a press release statement.

The offering was upsized, with gross proceeds expected to reach $128.7 million before underwriting discounts, commissions, and other expenses. All shares are being sold by Scribe Therapeutics. The underwriters have been granted a 30-day option to purchase up to an additional 1,287,000 shares at the IPO price.

Shares were set to begin trading on the Nasdaq Global Market on July 24, 2026, with the offering expected to close on July 27, 2026, subject to customary closing conditions.

Alongside the IPO, Scribe Therapeutics agreed to sell 500,000 shares at $15.00 per share in a concurrent private placement to Sanofi. That transaction is also expected to close on July 27, 2026, subject to customary closing conditions, including completion of the IPO. The IPO is not contingent on the private placement closing.

Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers for the offering.

Scribe Therapeutics focuses on CRISPR-based genetic medicines, with initial programs targeting cardiometabolic disease. The company has existing collaborations with Sanofi and Eli Lilly.

You May Also Be Interested In

• Zentalis Pharmaceuticals prices $80.5M public stock offering
• bioAffinity Technologies closes $4M private placement offering
• KKR prices secondary offering of 5 million BridgeBio shares